{
    "nctId": "NCT01439191",
    "briefTitle": "Study of Cipterbin\u00ae, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer",
    "officialTitle": "An Open-Label Randomized Phase II Study of Cipterbin\u00ae or Cipterbin\u00ae in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 109,
    "primaryOutcomeMeasure": "Overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* pathologic diagnosis breast cancer\n* HER2+ status defined as IHC3+ Staining or in situ hybridization positive at least 1 measurable lesion as per RECIST criteria\n* Adequate bone marrow function (absolute neutrophil count \\>1500/mm3, platelet count \\>100.000/mm3, hemoglobin \\>10gr/mm3)\n* Adequate liver (bilirubin \\<1.0 times upper limit of normal and SGOT/SGPT \\<2.5 times upper limit of normal) and renal function (creatinine \\<1.5mg/dl)\n* Adequate cardiac function (LVEF\\>50%). Normal electrocardiogram and absence of significant heart disease\n* age from 18 to 70y\n* Karnofsky performance score \u2265 60\n* Life expectancy of greater than 3 months\n* Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause.\n* signed ICF\n\nExclusion Criteria:\n\n* prior exposure vinorelbine for breast cancer\n* prior exposure trastuzumab for breast cancer\n* Prior chemotherapy and radiation therapy within the last 4 weeks before enrollment\n* use of any other investigational agents within the last 4 weeks before enrollment\n* symptomatic, central nervous system metastases\n* Hypersensitivity to trial medications\n* breastfeeding or pregnant",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}